Sweet's Syndrome (Acute Febrile Neutrophilic Dermatosis)
Clinical guidelines for managing neutrophilic dermatoses, evaluating IL-1 receptor pathway activation, dermal neutrophilic infiltration, and reviewing corticosteroid and anti-IL-1 therapies.
🧠 Standard of Care & Symptoms
Sweet's Syndrome, or Acute Febrile Neutrophilic Dermatosis, is an inflammatory skin condition characterized by the sudden eruption of painful skin lesions accompanied by fever and systemic symptoms.
- Presentation: Key diagnostic signs.
- *Painful Plaques/Nodules:* Eruptions of tender, red-to-purple papules, nodules, or plaques, typically distributed on the face, neck, and upper limbs. Lesions may have a pseudovesicular appearance due to severe upper dermal edema.
- *Abrupt Onset Fever:* High fever (>38°C) that frequently precedes or coincides with the development of skin lesions.
- *Extracutaneous Involvements:* Joint pain (arthralgias), muscle pain (myalgias), or eye inflammation (conjunctivitis/episcleritis).
- *Classifications:* Classic (idiopathic, associated with infection or IBD), malignancy-associated (most commonly AML), and drug-induced (often triggered by G-CSF).
🧬 Diagnostics & Neutrophilic Pathophysiology
Diagnosis requires a deep punch skin biopsy, laboratory screening for leukocytosis, and evaluation for potential secondary triggers.
- Diagnostic Markers: Key criteria.
- Skin Biopsy: Histopathological hallmark is a dense, diffuse infiltrate of mature neutrophils in the upper dermis, without evidence of true leukocytoclastic vasculitis. Severe papillary dermal edema is typical.
- Leukocytosis with Neutrophilia: CBC shows elevated white blood cell counts (>10,000/mm³) with absolute neutrophilia (>70% neutrophils).
- Inflammatory Markers: Markedly elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP).
Pathophysiology of Neutrophilic Eruption
The sudden accumulation of neutrophils in the skin is driven by dysregulated cytokine signaling:
- Cytokine Signaling Cascades: Lesions are characterized by high levels of local and systemic **Interleukin-1 (IL-1)**, **IL-6**, **IL-8**, and granulocyte colony-stimulating factor (**G-CSF**). These cytokines promote neutrophil production, activation, and migration into tissues.
- Role of G-CSF: Drug-induced Sweet's Syndrome is often caused by therapeutic administration of G-CSF. G-CSF stimulates the bone marrow to produce and release granulocytes, directly precipitating the cutaneous inflammatory response in susceptible individuals.
- Lack of Vasculitis: Unlike leukocytoclastic vasculitis, the neutrophilic infiltrate in Sweet's Syndrome does not destroy the walls of dermal blood vessels, representing a pure neutrophilic dermatosis.
💊 Steroid & Targeted IL-1 Therapies
Corticosteroids are highly effective at inducing rapid remission. Alternative anti-inflammatory agents are used for steroid-refractory or drug-induced cases.
Corticosteroid Interventions
- Systemic Steroids (Prednisone): The gold standard treatment. Prednisone (0.5 to 1.0 mg/kg/day orally) leads to rapid resolution of fever within 24-48 hours, and clearing of skin lesions over several weeks.
- Topical & Intralesional Steroids: High-potency topical steroids or intralesional triamcinolone injections are used for localized lesions to minimize systemic steroid side effects.
Alternative Systemic Options
- Potassium Iodide & Colchicine: Oral potassium iodide (900 mg/day) or colchicine (0.6 mg two to three times daily) are effective first-line non-steroid therapies that suppress neutrophil chemotaxis.
- Targeted IL-1 Blockade: In refractory, chronic, or malignancy-associated cases, targeted biologic inhibition of the IL-1 pathway using **Anakinra** (IL-1 receptor antagonist) is used to interrupt neutrophil recruitment.
🔬 Active Clinical Trials
Clinical trials are currently evaluating targeted interleukin inhibitors, oral JAK inhibitors, and therapeutic algorithms for malignancy-associated disease.
Evaluating the efficacy of daily subcutaneous Anakinra injections in inducing remission in patients with chronic, relapsing, or steroid-resistant Sweet's Syndrome.
Key Inclusion: Age 18 to 80, biopsy-proven Sweet's Syndrome, and failure of at least one course of oral corticosteroids.Investigating if blocking JAK1 downstream signaling of pro-inflammatory cytokines (IL-6, interferon-gamma) can suppress dermal neutrophil recruitment and clear skin lesions.
Key Inclusion: Age ≥ 18, active febrile neutrophilic dermatosis, and inadequate response to first-line non-steroid therapies.A randomized trial comparing the safety, speed of fever control, and recurrence rates of Anakinra versus standard oral Prednisone in newly diagnosed patients.
Key Inclusion: Age 18 to 75, active Sweet's Syndrome, and no prior systemic immunomodulatory treatment for this flare.🗺️ Next Steps After Diagnosis
If you have recently been diagnosed with Sweet's Syndrome, establish these clinical care pathways:
- Perform a Complete Blood Count (CBC): Confirm the presence of neutrophilia and rule out initial hematopoietic abnormalities.
- Evaluate for Malignancy: In adults presenting with severe or atypically distributed Sweet's Syndrome, consult an oncologist for age-appropriate screening, especially hematological screening (AML).
- Identify Drug Triggers: Review your active medications with your doctor, paying close attention to recent administrations of G-CSF or certain antibiotics.
- Plan a Tapering Steroid Schedule: If starting Prednisone, follow a gradual taper plan exactly to avoid rebound flares.
❓ Patient FAQ
Q: What causes Sweet's Syndrome?
A: In many cases, the cause is idiopathic (unknown). However, it is often triggered by an upper respiratory or gastrointestinal infection, an inflammatory condition like IBD, malignancy (such as leukemia), or exposure to certain medications like G-CSF.
Q: Is Sweet's Syndrome contagious?
A: No, Sweet's Syndrome is an inflammatory reaction and is not contagious. It cannot be passed from person to person.